about
OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophagesACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model.Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro.Osbpl8 deficiency in mouse causes an elevation of high-density lipoproteins and gender-specific alterations of lipid metabolismMast cells in vulnerable atherosclerotic plaques--a view to a kill.VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart.Mast cells: important players in the orchestrated pathogenesis of abdominal aortic aneurysms.Novel 6p21.3 Risk Haplotype Predisposes to Acute Coronary Syndrome.TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma.The R-Ras interaction partner ORP3 regulates cell adhesion.Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.Induction of local angiotensin II-producing systems in stenotic aortic valves.Dilated cardiomyopathy alters the expression patterns of CAR and other adenoviral receptors in human heart.Rab8 regulates ABCA1 cell surface expression and facilitates cholesterol efflux in primary human macrophages.Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves.Spatial distributions of lipids in atherosclerosis of human coronary arteries studied by time-of-flight secondary ion mass spectrometry.Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves.Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours.Low-expression variant of fatty acid-binding protein 4 favors reduced manifestations of atherosclerotic disease and increased plaque stability.p38δ MAPK: A Novel Regulator of NLRP3 Inflammasome Activation With Increased Expression in Coronary Atherogenesis.Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves.Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion.Imatinib treatment attenuates growth and inflammation of angiotensin II induced abdominal aortic aneurysm.TRIF adaptor signaling is important in abdominal aortic aneurysm formation.Mast cells associate with neovessels in the media and adventitia of abdominal aortic aneurysms.Morphology and histology of silent and symptom-causing atherosclerotic carotid plaques - Rationale and design of the Helsinki Carotid Endarterectomy Study 2 (the HeCES2)Outcome of Cardiac Sarcoidosis Presenting With High-Grade Atrioventricular BlockComplement regulation in human atherosclerotic coronary lesionsEndothelial Apoptosis Does Not Determine Symptom Status in Carotid Artery DiseaseHuman mast cell neutral proteases generate modified LDL particles with increased proteoglycan bindingDown-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failureImproved identification of endothelial erosion by simultaneous detection of endothelial cells (CD31/CD34) and platelets (CD42b)Increased expression of bradykinin type-1 receptors in endothelium of intramyocardial coronary vessels in human failing heartsVascular endothelial growth factor-secreting mast cells and myofibroblasts: a novel self-perpetuating angiogenic pathway in aortic valve stenosisImatinib mesylate alleviates diarrhea in a mouse model of intestinal allergyHistopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survivalReceptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung CancersSudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries
P50
Q28256750-304FEC71-1256-4BE5-8A98-79F941E64146Q33414426-9A1E93C4-F978-47C4-85CA-F5FB2AC865DEQ34325457-28D91E14-F116-4531-AF2A-55BE3193CB5CQ34648407-0516936C-FEC5-4614-9316-A881103376AEQ36924398-DDE46084-778B-42B8-9B80-B7DEA49B7D1EQ37644376-06939479-08FD-4809-A81E-1C37725ED370Q37826023-7AFA006D-EE3A-4EAD-A5E7-47FD4B9F430BQ38398347-027F37B4-4E2C-45A4-A17D-34AF87AB4381Q38740558-F4B10C63-97E5-495B-841B-9729480E98C3Q40013904-88318A6E-2311-4682-9605-A00C420EFCAFQ40367038-04A4EEB4-0D16-4192-A238-3CA4D6AD03A2Q42170216-7C472BF6-DA67-43FA-9275-3811C1EFF306Q45855492-6FC0EE06-5D12-4004-8733-ACAA19AA117AQ46079332-F289BBD1-3979-42BF-ABE9-0D0AF8FDA2AAQ46656595-0E08C8D5-B725-4411-9BBE-A67C398D5673Q46754289-8083B332-90CA-43A1-AAD6-3CA80DE97121Q46886153-A4519733-F917-4C00-84DF-B801A7C58B7FQ50005657-0D006AA8-399A-4374-B08D-F5FCEC405994Q50462674-A804730A-00E9-4ECC-8211-A5C0963ABF85Q51641034-A30C6607-B60C-484E-9ED7-E686D68934ABQ52571104-82CB7B5C-D793-4AF4-A6C2-C940DD892548Q52574343-3BB26969-B1B1-4C73-ACFD-E578D61E3437Q52874673-4B670B7D-77D4-4F79-9EA2-C8827C93CA0CQ52935604-826F358D-F1AA-4E2F-B62B-079ECDA45E72Q54478166-477E653F-50B1-47BF-835B-F4A8F1D087F7Q57133946-3BC19030-D547-4D36-8D10-293855D2C84AQ57824388-7152808E-984C-4EB3-BCA1-C001EFDBF778Q59244329-AA319206-3B8D-4A24-8BB8-FB9181BDA810Q61649739-1DF3472D-66CE-4189-9782-D6DD93F0F677Q62023716-3160DB32-1A86-405D-B758-C5DCDB721827Q74424752-85BF11C7-D03E-41C4-94F0-32CB2666A22AQ80320299-C8298718-96BF-43FA-9B5C-DB0BA3DCB050Q81667247-B67BE014-829F-47EE-9DC7-5F254873E796Q83366255-A3E06446-FE66-44F5-B3EB-41D7171DD4A8Q84399708-1DD43E12-74BA-48D4-B196-16755C19972CQ90111053-7C665617-7E23-4E41-B1CF-FCBEF99AFE02Q92000562-999135A0-AE99-4047-8990-B5F4BA39A3B9Q92963059-255A0A25-3267-43FA-B28B-E44A23A69B3F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mikko I Mäyränpää
@ast
Mikko I Mäyränpää
@en
Mikko I Mäyränpää
@es
Mikko I Mäyränpää
@nl
Mikko I Mäyränpää
@sl
type
label
Mikko I Mäyränpää
@ast
Mikko I Mäyränpää
@en
Mikko I Mäyränpää
@es
Mikko I Mäyränpää
@nl
Mikko I Mäyränpää
@sl
prefLabel
Mikko I Mäyränpää
@ast
Mikko I Mäyränpää
@en
Mikko I Mäyränpää
@es
Mikko I Mäyränpää
@nl
Mikko I Mäyränpää
@sl
P106
P31
P496
0000-0002-0877-9640